Cell kinetics was determined, as 3H-thymidine labeling index (LI), in hepatic lesions from 36 patients with primary colorectal carcinoma; LI values ranged from 0.9% to 23.5% and were normally distributed. Cell kinetics was not related to sex or age of the patient, or to liver function. For clinical studies the median LI value of 10% was used to separate slowly and rapidly proliferating lesions. Univariate analysis showed that patients radically resected and with a low LI tumor have a longer disease-free interval and a better probability of 12-month survival than those non-radically resected and with a high LI tumor. When treatment and cell kinetics were taken into consideration, the probability of 12-month survival was 100% for patients with slowly proliferating and radically resected hepatic metastases. Patients with rapidly proliferating tumors, regardless of type of treatment, had the worst prognosis.
INTRODUCTION
Hepatic metastases in patients with colorectal carcinoma always represent a poor prognostic factor for patient survival. However, the clinical course varies from a few months to some years.
Various classifications have been proposed 1-8, and biologic markers and pathologic features indicative of risk have been analyzed in multivariate analyses and ranked 9 10,11 according to their relative ability to predict survival Cell kinetics, a variable ofprognostic relevance already proved in some human tumor [12] [13] [14] [15] [16] [17] [18] types, has been determined in primary colorectal tumors but it has never been investigated in hepatic metastases. With the present study, we proposed to define the potential proliferative activity of hepatic metastases from colorectal carcinoma, in the different clinico-pathologic situations, and to investigate its prognostic relevance and its relative importance compared with conventional factors in predicting clinical outcome.
*Address reprint requests to: Rosella Silvestrini The relative prognostic relevance of treatment and cell kinetics, as the two most important prognostic factors for this series ofpatients, was analyzed. Bivariate analysis showed that cell kinetics was an additional significant discriminant of survival within a group of patients with resectable metastases (Figure 3 ). In fact, all patients with low LI hepatic lesions were alive at 12 months. Conversely, only about one-third of patients with high LI metastases have a probability to survive at that time. Median time to progression (TTP) was not reached in the former subgroup, and it was 6 months in the latter. In patients with unresectable metastases, median TTP and survival rate at 12 months for patients with low LI lesions were double those observed for patients with high LI lesions. The difference was not statistically different ( Figure 4 ). (Table 4) . It appears that the presented method has a potential for better stratification and for better selection of treatment of patients with colorectal liver cancer. As stressed by the
